What types of policy changes does Aetna issue?

Aetna regularly publishes coverage updates including prior authorization requirement changes, billing code additions or deletions, plan-type coverage modifications, and clinical policy revisions. PolicyChanges.app monitors these notices and summarizes the impact for providers.

How often does Aetna update its policies?

Aetna typically releases policy bulletins on a rolling basis throughout the year. Our system checks for new updates daily and adds them to this feed as soon as they are identified.

How many Aetna policy changes are tracked here?

This page currently tracks 50 documented Aetna policy changes. New items are added as they are identified.

What should I do when Aetna changes a prior authorization policy?

Review each change's effective date and action-required notes. Update your billing and clinical workflows before the effective date to avoid claim denials. Each policy detail page on PolicyChanges.app includes a plain-English summary and action items.

Aetna Policy Changes 2026 | Prior Auth & Coverage Updates

Aetna Policy Changes & Prior Auth Updates

We track 50 documented policy changes from Aetna across AL, AR, AZ, CA, CO and 5 more states. Each entry includes an AI-generated plain-English summary, effective date, affected billing codes, and a direct link to the original Aetna notice. Use the related links below to narrow results by specialty or state, or sign up for a free daily alert to receive new Aetna updates automatically.

High impact

Transcranial Magnetic Stimulation and Cranial Electrical Stimulation (CPB 0469, reviewed 2026-07-17)

Aetna·Effective Jul 17, 2026

Aetna updated its TMS (Transcranial Magnetic Stimulation) coverage policy (CPB 0469) effective 2026-07-17, establishing strict medical necessity criteria including FDA-cleared device requirement, age 15+ restriction, confirmed severe MDD diagnosis with standardized rating scales, specific antidepressant trial requirements (2 different classes for adults; 2 trials plus psychotherapy or augmentation for adolescents), maximum 36 sessions (30 treatment + 6 tapering), psychiatrist/PMHNP oversight requirements, and qualified operator supervision. The policy also clarifies contraindications, retreatment criteria, re-mapping allowances, and designates several procedures as experimental (accelerated TMS, MRI-guided TMS, ketamine adjunctive use, EEG-combined TMS, navigated TMS).

OfficeLink Updates - September 2026 newsletter

Plozasiran (Redemplo) (CPB 1096, reviewed 12-2026-03)

Lunsotogene Parvec-cwha (Otarmeni) (CPB 1103, reviewed 12-2026-08)

Nipocalimab-aahu (Imaavy) (CPB 1083, reviewed 2026-08-11)

Rozanolixizumab-noli (Rystiggo) (CPB 1035, reviewed 2026-08-11)

Inebilizumab-cdon (Uplizna) (CPB 0975, reviewed 2026-08-11)

Ravulizumab-cwvz (Ultomiris) (CPB 0946, reviewed 2026-08-11)

Eculizumab (CPB 0807, reviewed 2026-08-11)

Efgartigimod Alfa-fcab (Vyvgart) and Efgartigimod Alfa and Hyaluronidase-qvfc (Vyvgart Hytrulo) (CPB 1002, reviewed 2026-08-11)

Transthyretin-Mediated (ATTR) Amyloidosis (CPB 0939, reviewed 2026-08-10)

Reslizumab (Cinqair) (CPB 0907, reviewed 2026-08-10)

Magnetic Resonance Imaging (MRI) of the Breast (CPB 0105, reviewed 2026-08-06)

Tezepelumab-ekko (Tezspire) (CPB 1003, reviewed 2026-08-06)

Lumbar Traction Devices (CPB 0569, reviewed 2026-08-06)

Amivantamab-vmjw (Rybrevant) and Amivantamab and Hyaluronidase-lpuj (Rybrevant Faspro) (CPB 0995, reviewed 2026-08-05)

Mepolizumab (Nucala) (CPB 0897, reviewed 2026-08-05)

Catheter-Directed Cardiac Procedures (CPB 0292, reviewed 2026-08-04)

Cryoablation (CPB 0100, reviewed 2026-08-04)

Nonstandard Laboratory Test Panels (CPB 0499, reviewed 2026-08-03)

Laser Neurolysis (CPB 0552, reviewed 2026-08-03)

Ambulatory Assist Devices: Canes, Crutches, and Walkers (CPB 0505, reviewed 2026-08-03)

Canakinumab (Ilaris) (CPB 0881, reviewed 2026-08-03)

Varicose Veins (CPB 0050, reviewed 2026-08-03)

Nusinersen (Spinraza) (CPB 0915, reviewed 2026-07-31)

Hip Preservation Surgery (CPB 0736, reviewed 2026-07-31)

Selected Kidney Function Tests (CPB 0775, reviewed 2026-07-31)

Golimumab (Simponi and Simponi Aria) (CPB 0790, reviewed 2026-07-31)

Vascular Endothelial Growth Factor Inhibitors for Ocular Indications (CPB 0701, reviewed 2026-07-30)

Urological Supplies (CPB 0533, reviewed 2026-07-30)

Spinal Surgery: Laminectomy and Fusion (CPB 0743, reviewed 2026-07-30)

Skin and Soft Tissue Substitutes (CPB 0244, reviewed 2026-07-29)

Radiofrequency Tumor Ablation (CPB 0492, reviewed 2026-07-29)

Electrodiagnostic Testing (CPB 0502, reviewed 2026-07-29)

Positron Emission Tomography (PET) (CPB 0071, reviewed 2026-07-28)

Nerve Blocks (CPB 0863, reviewed 2026-07-23)

Headaches: Invasive Procedures (CPB 0707, reviewed 2026-07-23)

Endoscopic Ultrasonography (CPB 0446, reviewed 2026-07-22)

Obesity Surgery (CPB 0157, reviewed 2026-07-21)

Infliximab (CPB 0341, reviewed 2026-07-21)

Cardiac Computed Tomography (CT), Coronary CT Angiography, Calcium Scoring and CT Fractional Flow Reserve (CPB 0228, reviewed 2026-07-21)

Obstructive Sleep Apnea in Adults (CPB 0004, reviewed 2026-07-21)

Transcranial Magnetic Stimulation and Cranial Electrical Stimulation (CPB 0469, reviewed 2026-07-17)

Maternal Biomarker Screening for Fetal Conditions (CPB 0464, reviewed 2026-07-17)

Hip Arthroplasty (CPB 0287, reviewed 2026-07-17)

Gender Affirming Surgery (CPB 0615, reviewed 2026-07-17)

Magnesium Sulfate Injections and Terbutaline Pump for Preterm Labor (CPB 0468, reviewed 2026-07-17)

Linvoseltamab-gcpt (Lynozyfic) (CPB 1089, reviewed 2026-07-17)

Upper Limb Prostheses (CPB 0399, reviewed 2026-07-16)

Obsolete and Unreliable Tests and Procedures (CPB 0438, reviewed 2026-07-16)

Foot Orthotics (CPB 0451, reviewed 2026-07-16)